19 December 2023: Original Paper
Allogeneic Hematopoietic Stem Cell Transplantation Can Improve Prognosis of Extramedullary Infiltration Positive t(8;21) Acute Myeloid Leukemia
Xiaokai Wang 1BCDEF* , Xuetong Xu 2BCDF* , Hao Zhang 3CDF* , Wei Zhou 45BC , Dan Gong 6BD , Chengying Zhu 78CF , Dejun Zhou 9ADFG* , Guofeng Chen 9ABCDEFG*DOI: 10.12659/AOT.942197
Ann Transplant 2023; 28:e942197
Table 1 Clinical characteristics in t(8;21) AML patients with EMI at diagnosis.
| TotalN=51 | No allo-HSCTn=36 | Allo-HSCTn=15 | P-value | |
|---|---|---|---|---|
| Age, years, No. (%) | 0.073 | |||
| ≤14 | 12 (23.5%) | 6 (16.7%) | 6 (40.0%) | |
| ≥15 | 39 (76.5%) | 30 (83.3%) | 9 (60.0%) | |
| Sex, No. (%) | 0.794 | |||
| Male | 32 (62.7%) | 23 (63.9%) | 9 (60.0%) | |
| Female | 19 (37.3%) | 13 (36.1%) | 6 (40.0%) | |
| WBC, ×10/L, median (range) | 11.4 (1.2–77.8) | 9.4 (1.2–77.8) | 19.1 (3.3–39.9) | 0.302 |
| HB, g/L, median (range) | 84.0 (19.0–133.0) | 86.0 (19.0–133.0) | 80.0 (47.0–126.0) | 0.825 |
| PLT, ×10/L, median (range) | 33.0 (2.0–291.0) | 34.0 (4.0–291.0) | 27.0 (2.0–116.0) | 0.350 |
| Blasts in BM,%, median (range) | 49.5 (14.5–94.0) | 52.0 (14.5–94.0) | 44.0 (19.5–84.0) | 0.378 |
| EMI sites, No. (%) | 0.595 | |||
| CNS | 15 (29.4%) | 12 (33.3%) | 3 (20.0%) | |
| Bone | 8 (15.7%) | 7 (19.4%) | 1 (6.7%) | |
| Skin | 5 (9.8%) | 3 (8.3%) | 2 (13.3%) | |
| Lymph node | 4 (7.8%) | 3 (8.3%) | 1 (6.7%) | |
| Liver | 2 (3.9%) | 1 (2.8%) | 1 (6.7%) | |
| Spleen | 2 (3.9%) | 1 (2.8%) | 1 (6.7%) | |
| Orbit | 1 (2.0%) | 0 (0.0%) | 1 (6.7%) | |
| Multiple infiltration sites | 14 (27.5%) | 9 (25.0%) | 5 (33.3%) | |
| Numbers of additional abnormal karyotype, No. (%) | 0.538 | |||
| 0 | 19 (37.3%) | 13 (36.1%) | 6 (40.0%) | |
| 1 | 16 (31.4%) | 11 (30.6%) | 5 (33.3%) | |
| 2 | 4 (7.8%) | 4 (11.1%) | 0 (0.0%) | |
| ≥3 | 1 (2.0%) | 1 (2.8%) | 0 (0.0%) | |
| Not assessed | 11 (21.6%) | |||
| Type of karyotype, No. (%) | 0.087 | |||
| T(8;21)-only | 19 (37.3%) | 13 (44.8%) | 6 (54.5%) | |
| Additional -Y | 8 (15.7%) | 6 (20.7%) | 2 (18.2%) | |
| Additional -X | 4 (7.8%) | 4 (13.8%) | 0 (0.0%) | |
| Additional other abnormal karyotype | 4 (7.8%) | 1 (3.4%) | 3 (27.3%) | |
| Complex karyotype* | 5 (9.8%) | 5 (17.2%) | 0 (0.0%) | |
| Not assessed | 11 (21.6%) | |||
| KIT mutation, No. (%) | 0.756 | |||
| Negative | 35 (68.6%) | 25 (69.4%) | 10 (66.7%) | |
| Positive | 12 (23.5%) | 8 (22.2%) | 4 (26.7%) | |
| Not assessed | 4 (7.8%) | |||
| WT1, No. (%) | 0.336 | |||
| Negative | 36 (70.6%) | 24 (66.7%) | 12 (80.0%) | |
| Positive | 11 (21.6%) | 9 (25.0%) | 2 (13.3%) | |
| Not assessed | 4 (7.8%) | |||
| FLT3-ITD, No. (%) | 0.510 | |||
| Negative | 46 (90.2%) | 32 (88.9%) | 14 (93.3%) | |
| Positive | 1 (2.0%) | 1 (2.8%) | 0 (0.0%) | |
| Not assessed | 4 (7.8%) | |||
| * Complex karyotype was defined as ≥3 clonal chromosomal abnormalities. EMI – extramedullary infiltration; allo-HSCT – allogeneic hematopoietic stem cell transplantation; WBC – white blood cell count; HB – hemoglobin; PLT – platelets; BM – bone marrow; EMI – extramedullary infiltration; CNS – central nervous system; -Y – loss of Y chromosome; -X – loss of X chromosome. | ||||